← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-4 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)
Muscular Dystrophy Association·Muscular Dystrophies
1 trials·t½ 15 h
Overview
Program
Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
Overview
Company
Muscular Dystrophy Association
Overview
Modality
CGT
Overview
Target
Muscular Dystrophies
Overview
Indication
Muscular Dystrophies
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
PK/PD
Half-life
15 h
Toxicology
Major finding
Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study.. To assess the sustained virologic response (SVR12) and safety profile of 12-week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)-infected patients across genotypes in Northwest China. This prospective cohort study (2023-2024) enrolled HCV patients…
Clinical
Safety signal
Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study.. To assess the sustained virologic response (SVR12) and safety profile of 12-week coblopasvir/sofosbuvir (COB/SOF) therapy in hepatitis C virus (HCV)-infected patients across genotypes in Northwest China. This prospective cohort study (2023-2024) enrolled HCV patients…
Clinical
Program phase
PHASE_1